Abstract-Hypertension is one of the most common complex genetic disorders. We have described previously 38 single nucleotide polymorphisms (SNPs) with suggestive association with hypertension in Japanese individuals. In this study we extend our previous findings by analyzing a large sample of Japanese individuals (nϭ14 105) for the most associated SNPs. We also conducted replication analyses in Japanese of susceptibility loci for hypertension identified recently from genome-wide association studies of European ancestries. Association analysis revealed significant association of the ATP2B1 rs2070759 polymorphism with hypertension (Pϭ5.3ϫ10 Ϫ5 ; allelic odds ratio: 1.17 [95% CI: 1.09 to 1.26]). Additional SNPs in ATP2B1 were subsequently genotyped, and the most significant association was with rs11105378 (odds ratio: 1.31 [95% CI: 1.21 to 1.42]; Pϭ4.1ϫ10
B
ecause of its large impact on a number of cardiovascular diseases, hypertension is a major contributor to global health burden. Because hypertension is one of the most prevalent complex genetic disorders, with a heritability of Յ60% based on the estimation by 24-hour blood pressure (BP) readings, 1 numerous studies, including recent genomewide association studies (GWAS), [2] [3] [4] [5] [6] have attempted to identify genetic variation associated with human BP levels.
Except for rare mendelian forms of hypertension, 7 the estimated effects of each genetic factor on BP levels have been found to be small in the general population (typically Ͻ1.0 mm Hg on systolic BP [SBP] and Ͻ0.5 mm Hg on diastolic BP [DBP] per risk allele). However, multiple risk alleles are known to have a cumulative impact on several complex traits, including BP and hypertension risk. 3 In addition, it is anticipated that identification of novel susceptibility genes would lead to further understanding of disease pathogenesis.
As a part of a series of nationally based cooperative projects, the Millennium Genome Project (Millennium GPJ), we conducted multiple candidate gene analyses to identify susceptible genes and polymorphisms for hypertension. In a previously reported study, 6 we focused on 307 genes, which were genes encoding components of signal transduction pathways potentially related to BP regulation, including receptors, soluble carrier proteins, binding proteins, channels, enzymes, and G proteins. That study identified 38 single nucleotide polymorphisms (SNPs) as suggestively associated with hypertension by analysis of 758 hypertensive patients and 726 normotensive controls. 6 To extend our previous study, we have now genotyped all 38 of the SNPs in a replication panel composed of 1929 hypertensives and 1993 normotensives and have taken forward validated SNPs with further genotyping in a large Japanese genetic epidemiological cohort sample (nϭ14 105). An in silico validation analysis of our most promising loci was performed using the Global Blood Pressure Genetics (Global BPgen) consortium data set, a large-scale GWAS of samples of European descent. 2 Furthermore, we also conducted a replication analysis of recent European GWAS-derived susceptible loci for hypertension from Global BPgen 2 and CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) GWAS 3 in a Japanese large-scale general population sample ( Figure S1 , available in the online Data Supplement at http://hyper.ahajournals.org).
Methods

Case and Control Subjects (Screening Panel)
Details of the screening panel subjects have been described previously. 6 Briefly, hypertensive patients and normotensive controls were recruited in the Asahikawa, Tokyo, Osaka, and Hiroshima regions of Japan according to the following criteria. Hypertensive subjects (nϭ758) had a previous diagnosis of hypertension at between 30 and 59 years of age and were either being treated with antihypertensive medication or had a SBP Ͼ160 mm Hg and/or DBP Ͼ100 mm Hg. They had a family history of hypertension in their parents and/or siblings and were not obese (body mass index [BMI] Ͻ25 kg/m 2 ). Normotensive controls (nϭ726) aged Ͼ45 years were recruited from the same regions. These individuals have never been treated with antihypertensive medications, and their SBP was Ͻ120 mm Hg and DBP Ͻ80 mm Hg. They had no family history of hypertension. All of the subjects were unrelated and were native Japanese.
Cohort-Based Population Samples
Seven independent study cohorts for cardiovascular diseases and related risk factors were combined to compose a large-scale Japanese genetic epidemiological population sample of 14 105. The Ohasama, Shigaraki, Takashima, Suita, and Nomura studies are general population-based genetic epidemiological studies. The study subjects were recruited via a medical checkup process for community residents. The 2 other cohorts, Yokohama and Matsuyama, are derived from employees of large manufacturing industries. The clinical parameters used in this study were obtained from personal health records during annual medical checkups. Further details of the study cohorts are described in the online Data Supplement.
Nested Case and Control Subjects Derived From the Cohort-Based Sample (Replication Panel)
Hypertensive cases and normotensive controls were chosen from the cohort-based population samples described above (nϭ11 569; the Suita study was excluded because of ethical issues). The selection criteria of the hypertensive and normotensive subjects were as follows: hypertensive subjects (nϭ1929) aged Յ64 years and either treatment with antihypertensive medication and/or SBP Ͼ160 mm Hg and/or DBP Ͼ90 mm Hg; normotensive subjects (nϭ1993) aged Ն40 years and having SBP Ͻ120 mm Hg and DBP Ͻ80 mm Hg; and no current use of antihypertensive medication and free from any history of cardiovascular disease.
Global BPgen (In Silico) Analyses
To investigate cross-validation of the most promising SNPs, we obtained results for 4 SNPs in the ATP2B1 gene from the Global BPgen consortium, a study that is composed of 17 GWAS studies with 34 433 individuals of European descent. A detailed description of the study design and phenotype measurement for all of the cohorts has been reported previously. 2 
Validation of Published BP Polymorphisms in the Japanese Millennium Cohort
Thirteen loci have been identified recently and robustly validated for association with BP and hypertension in recent large-scale GWAS of European samples, by the Global BPgen consortium 2 and the CHARGE consortium. 3 From the associated SNPs reported at these 13 loci, we selected SNPs expected to have minor allele frequencies in Japanese samples Ͼ0.10, based on the HapMap database (JPT only, Public Release No. 27) 8 : FGF5 rs1458038, CYP17A1 rs1004467, CSK rs1378942, PLCD3 rs12946454, PLEKHA7 rs381815, ULK4 rs9815354, and CSK-ULK3 rs6495122. These 7 SNPs were genotyped in the Japanese population-based cohort sample to test whether the same associations exist in samples of Japanese ancestry.
Genotyping
Genomic DNA was extracted from peripheral blood. All of the SNPs were analyzed by TaqMan probe assays (Applied Biosystems Co, Ltd) using commercially available primers and probes purchased from the Assay-on-Demand system. The fluorescence level of PCR products was measured using an ABI PRISM 7900HT sequence detector.
Ethical Considerations
All of the study procedures were approved by the ethics committee of each university or research institute. Written informed consent was obtained from all of the participating subjects.
Ex Vivo Expression Analysis of ATP2B1 mRNA
Umbilical artery smooth muscle cells were isolated from umbilical cords obtained at delivery (nϭ34). Expression levels of ATP2B1 mRNA were analyzed by RT-PCR using a relative quantification method. Further details of the ex vivo expression analysis are described in the online Data Supplement.
Statistical Analysis
At each SNP, frequency differences in each genotype among hypertensive and normotensive subjects were assessed using a 2 test. Linkage disequilibrium (LD) coefficients were calculated using the Haploview software (Broad Institute). 9 Adjusted odds ratios for hypertension, as well as coefficients and SEs for SBP and DBP, were calculated using logistic and linear multiple regression analysis, adjusting for sex, age, age 2 , BMI, and cohort variables, using additive (1 degree of freedom) and genotypic (2 degrees of freedom) genetic models. Adjustment for treatment with antihypertensive medication was achieved by adding fixed constants to measured values (ϩ15 mm Hg for SBP and ϩ10 mm Hg for DBP). 10 The Global BPgen data and statistical methods have been described elsewhere. 2 Meta-analysis was performed assuming fixed effects and using inverse variance weights. An unweighted genetic risk score based on 4 SNPs (ATP2B1 rs1105378, FGF5 rs1458038, CYP17A1 rs1004467, and CSK rs1378942) was calculated by adding the number of risk alleles showing higher BP values. Risk allele of each SNP was defined as follows: ATP2B1, C allele; FGF5, T allele; CYP17A1, A allele; and CSK, C allele. The CSK-ULK3 SNP rs6495122 showing positive association with BP trait and hypertension was not included in the calculation of genetic risk score, because the strong LD with the CSK SNP rs1378942 (DЈϭ0.884; r 2 ϭ0.731) is most parsimoniously explained by both SNPs tagging a single risk variant. Differences in mRNA expression levels among the ATP2B1 rs1105378 genotype were assessed by ANOVA. The statistical analyses were performed using a commercially available statistical software package (JMP version 8, SAS Institute).
Results
Replication Genotyping
The clinical characteristics of the replication panel chosen from the cohort-based population samples (Table S1 , available in the online Data Supplement) are shown in Table S2 . Stringent case and control definitions, corresponding with the extreme upper Ϸ17% and lower Ϸ17% of the general population, were used to maximize power for fixed genotyping costs. 11 Thirty-six SNPs were successfully genotyped, and results for all of the SNPs are shown in Table S3 . Significant association was observed for the ATP2B1 rs2070759 polymorphism located in intron 8 (Pϭ4.4ϫ10
Ϫ4 ; allele odds ratio [OR]: 1.18 [95% CI: 1.07 to 1.29]). Several other SNPs also showed marginally significant association; however, the P values did not reach statistical significance after application of Bonferroni correction for multiple comparisons (threshold: 0.05/36ϭ0.0014; Table S3 ; we note that no other SNPs are significant if the less conservative Benjamini-Hochberg procedure is used to control the false discovery rate at 0.05). Although, the replication results in the less-strict nested case-control sample chosen from the same population sample have been reported in our previous article, 6 the association was recalculated to narrow down the SNPs to be applied to the following dense SNP analysis.
Dense SNP Analysis of the ATP2B1 Gene
To more precisely identify the SNP or SNPs increasing susceptibility for hypertension, we performed "de novo" genotyping of a dense SNP panel around marker rs2070759 in individuals from the original screening panel (Table S4 ). 6 Forty-one tag SNPs located in a 167-kb region around rs2070759 were selected using the HapMap database (Table  S5) . 8 Among the 27 SNPs polymorphic in our Japanese sample, the most significant association was observed with rs11105378; this yielded an allelic P value of 6.3ϫ10 Ϫ5 (OR: 1.37 [95% CI: 1.17 to 1.60]; Table 1 and Figure S2 ).
The most associated SNP and the 4 others from the dense SNP analyses were subsequently genotyped in the replication panel. Significant association of rs11105378 was confirmed in the replication panel with an allelic P value of 1 ϭ0.59), located within the same LD block, were also significantly associated with hypertension ( Table 1 ). The strong LD between associated SNPs suggests a single true association signal in this region.
We examined for possible association of SNPs in the ATP2B4 gene, a well-investigated isoform of the ATP2B1 gene, with hypertension in the screening panel. We observed no significant correlation with the 17 SNPs analyzed, which were selected using the HapMap database (Table S6) .
Population-Based Meta-Analyses of ATP2B1 SNPs
The complete Japanese population-based sample was subsequently genotyped for the 4 most significant SNPs in Table S7 ).
We next evaluated the effect of the most associated SNP, rs11105378, on BP levels in the Millennium GPJ cohort ( ) were also independently associated with DBP levels. We depict the covariate adjusted mean BP levels by rs11105378 genotype in Figure S3 . Results of each cohort separately are summarized in Table S8 . We next performed a meta-analysis of data from the Millennium GPJ and 2 large epidemiological studies (Global BPgen and CHARGE; Table 2 ). Results show the per-allele differences in SBP and DBP to be Ϸ1.0 and 0.5 mm Hg, respectively.
Genotype-Specific Differences in Ex Vivo Expression of ATP2B1 mRNA
Differences in ATP2B1 mRNA expression in umbilical artery smooth muscle cells among rs11105738 genotype are shown in Figure 1 . Assuming a recessive genetic model, cells homozygous for T allele showed significantly higher levels of Coefficients and SE for SBP and DBP were calculated under the additive model using multiple regression analysis adjusted for age, age 2 , sex, and BMI. In both Millennium GPJ and Global BPgen, adjustment for treatment with antihypertensive medication was achieved by adding fixed constants to measured values (ϩ15 mm Hg for SBP and ϩ10 mm Hg for DBP). 2 In the Japanese Millennium GPJ and also for some cohorts within Global BPgen, cohort variables were also adjusted to avoid residual population stratification.
*Results of the CHARGE Study were obtained from the published article. 3 CC (16) CT (13) TT ( Ex vivo expression analysis of ATP2B1 mRNA. Graphs depict the log 2 relative expression levels of the ATP2B1 mRNA in umbilical artery smooth muscle cells obtained by normalizing to GAPDH. Genotype of ATP2B1 rs11105378 of each sample was analyzed by direct sequencing using isolated genomic DNA from umbilical artery smooth muscle cells.
ATP2B1 mRNA as compared with cells carrying 1 or 2 C alleles (Pϭ0.031; see Figure 1 ). Under an additive genetic model, the overall P value was marginally significant (Pϭ0.091).
Replication Analysis of European GWAS-Derived Susceptible SNPs in Japanese
We next conducted a replication analysis in the Millennium GPJ, in which we tested associated SNPs identified in recent large-scale European GWAS by the Global BPgen 2 and the CHARGE consortia. 3 From the 7 most promising SNPs of which the minor allele frequency in Japanese was Ͼ0.10 based on the HapMap database, 4 SNPs, namely, FGF5 rs1458038, CYP17A1 rs1004467, CSK rs1378942, and CSK-ULK3 rs6495122, showed significant association in either binary trait analyses (Tables S9) or quantitative trait analysis  (Table 3 and S10). The most significant association was observed with FGF5 rs1458038; this yielded a P value of 1.6ϫ10
Ϫ8 (ϩ1.33 mm Hg) with SBP and 1.8ϫ10
Ϫ7
(ϩ0.73 mm Hg) with DBP in the Millennium GPJ cohort, and the effect size was greater than that of Europeans (Table 3) . Meta-analysis of both study panels with data from Global BPgen indicated further significant associations.
Multiple Regression Analysis for BP Trait and Hypertension in Japanese
To clarify whether the 4 susceptibility SNPs (ATP2B1, FGF5, CYP17A1, and CSK) were independently associated with BP traits and hypertension, multiple regression analysis was performed with possible covariates (Table S11) . After adjustment for age, age 2 , sex, BMI, and drinking habits, this analysis confirmed that all 4 of the SNPs were independent determinants for both BP traits and hypertension.
Combined Effect of Risk Genotypes on Hypertension
A risk score for 4 susceptible genotypes was calculated to evaluate their combined effects on hypertension. ORs asso- Ϫ15 ). The distribution of the Japanese population sample among the number of risk genotypes is shown in Figure S4 .
Discussion
The present study has identified SNPs located upstream or within the ATP2B1 gene as strong susceptibility polymorphisms for hypertension in Japanese. These are findings that have also been reported recently in individuals of European descent 3 and in Koreans. 4 Although numerous studies have attempted to identify genetic markers for hypertension over the past 2 decades, there has been little cross-validation of loci in different ethnic groups so far except for mendelian forms of hypertension. The SNPs in ATP2B1 identified in this study showed significant association in large-scale studies in populations with different ancestries and using different discovery approaches, including GWAS in the CHARGE consortium and the Korean study and an independent candidate gene analysis in our present study. Similar findings in different ethnic groups with different methods further strengthen these findings and indicate the ATP2B1 gene region as a susceptibility locus of likely global significance for BP variation and development of hypertension. Two replication results very recently reported by another Japanese group 12 and a Korean group 13 also indicated the disease susceptibility of ATP2B1 SNPs located in the same LD block.
No biological data have been provided whether SNP rs1105378 or other SNPs in strong LD have any effect on the transcriptional activity or transcriptional regulation of the ATP2B1 gene. Furthermore, although alternative splicing has been found to generate several variants of ATP2B1 mRNA, 14 the SNP associations that we have observed do not shed light on whether this is a potential mechanism for affecting BP. Our data first showed that the effect of SNPs on ATP2B1 gene expression levels is a potential mechanism by which disease-associated SNP alleles cause the phenotypic changes. Changes in the ATP2B1 gene product levels are involved in BP regulation. We found no microRNA harboring rs11105378 in the miRBase database. 15 The ATP2B1 (so-called PMAC1) gene encodes the plasma membrane calcium ATPase isoform 1, which removes bivalent calcium ions from eukaryotic cells against very large concentration gradients and plays a critical role in intracellular calcium homeostasis. Although pathophysiological implications of ATP2B1 gene products on the development of hypertension are uncertain, it has been reported that inhibition of ATP2B1 by the selective inhibitor caloxin 2A1 showed endothelium-dependent relaxation of rat aorta by increasing cytosolic Ca 2ϩ concentration and consequent activation of endothelial NO synthase. 16 Other information on the role of ATP2B1 has been obtained from experiments using bladder smooth muscle cells: contractility measurements on these cells have documented the important role of ATP2B1 in the extrusion of Ca 2ϩ after carbachol stimulation or depolarization with potassium chloride. 17 These reports suggest altered vascular reactivity as a plausible explanation for disease susceptibility of ATP2B1 gene.
In mammals, calcium ATPase isoforms are encoded by Ն4 separate genes (ATP2B1 to ATP2B4). 18 It has been reported that overexpression of the human ATP2B4 gene in arterial smooth muscle cells in mice increases vascular reactivity and BP partly because of negative regulation of neuronal NO synthase. 19 We, therefore, examined the possible association of ATP2B4 gene polymorphisms with hypertension by using the screening panel. However, no significant correlation was observed in the 17 SNPs analyzed, which were selected by reference to the HapMap database. The pathophysiological association of plasma membrane Ca 2ϩ pump with BP regulation may be isoform specific.
Numerous studies, including the recent GWAS, [3] [4] [5] [6] have attempted to identify genetic variations associated with human BP levels. At present, it is not clear to what extent findings from GWAS in one population can be extrapolated ORs for hypertension according to the number of risk genotypes Number of risk genotype was calculated by the following 4 SNPs: ATP2B1 rs1105378, FGF5 rs1458038, CYP17A1, rs1004467, and CSK rs1378942. Hypertensive subjects were defined as being treated with antihypertensive medication, SBP Ն140 mm Hg, or DBP Ն90 mm Hg; normotensive subjects were defined as all not treated with antihypertensive medication, SBP Յ120 mm Hg, and DBP Յ85 mm Hg. 2 Adjusted OR for hypertension and BP levels were calculated using logistic and linear multiple regression analysis, adjusting for sex, age, age 2 , BMI, and cohort variables. Frequency of hypertension and P values for the hypertension odds are shown in the top of column and the bottom of square, respectively.
to other populations with different lifestyles and genetic background. However, the present study provides a crossvalidation of 4 of 7 SNPs (most likely representing 3 of 6 independent signals) derived from European GWAS. Replication studies in other Japanese 12 and Korean 13 populations also reported the cross-validation of European GWASderived SNP. Conservation of susceptible loci for hypertension was independent of ethnic background. This finding suggests an existence of unidentified common etiology of essential hypertension in relation to the susceptible genes and their physiological pathways.
Although 20 serum lipid levels, 21 and serum uric acid levels. 22 We reported previously that the findings of the cross-sectional analysis revealed a similar association in the longitudinal analysis 23 ; the fat mass and obesityassociated gene polymorphism was an independent risk factor for the future development of obesity after adjustment for possible confounding factors. The present cross-sectional study cannot address the question of whether the ATP2B1 polymorphism and other susceptible variants predict future development of hypertension. However, recent articles investigating a prognostic significance of susceptible variants for type 2 diabetes mellitus 24 and cardiovascular disease 25 showed poor predictive performance of common variants in spite of the high OR observed in subjects carrying multiple risk alleles. A small proportion of the genetically high-risk persons attributed to independent inheritance of risk alleles may make it difficult to discriminate intermediate-risk persons. Genetic information may be most useful to identify a high-risk individual's need for early intervention.
Several definitions of hypertension were used in this study to explore susceptible SNPs with modest effects and to further validate the susceptibility. Since it was expected to be underpowered to detect the effects of common variants in a dichotomized analysis with slightly elevated BP, subjects with high normal BP were excluded from the 65 347 casecontrol analyses. All of the alleles associated with hypertension in a dichotomized analysis (Table S7) were also associated with BP levels (Table 2) . Our methodology may, thus, be appropriate to identify susceptible variants for hypertension.
Perspectives
We have identified SNPs located in the ATP2B1 gene region as susceptibility loci for hypertension in Japanese using a multistage association study, an association that has now been confirmed across different ethnic groups. Differences in the ex vivo ATP2B1 mRNA expression levels further supported the disease susceptibility of SNP rs1110578. We also replicated the susceptibility of the European GWAS-derived SNPs in Japanese. Because hypertension is a trait that is preventable by dietary and exercise interventions, early detection of at-risk populations using genetic information may be useful in preventing future hypertension-related diseases.
SUPPLEMENTAL METHODS
ex vivo expression analysis of ATP2B1 mRNA We obtained 34 umbilical cords at delivery (Kosei General Hospital). Umbilical arteries were excised from the cords and cut into small pieces. Umbilical artery smooth muscle cells (UASMCs) were separated using Hanks buffer containing 2 mg/ml collagenase and cultured in HuMedia-SG (Kurabo, Osaka, Japan) supplemented with epithelial growth factor (0.5 ng/ml), basic fibroblast growth factor (2 ng/ml), insulin (5 μg/ml), antibiotics and 5% fetal bovine serum. Total RNAs was extracted from UASMCs during early passages using TRIzol reagent according to manufacturer's instructions (Invitrogen, Carlsbad, CA). First-strand cDNA was synthesized from 500 ng of the total RNA using a PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio, Shiga, Japan), and then diluted five times for subsequent real-time PCR (RT-PCR). RT-PCR was performed using TaqMan Gene Expression Assays on a 7900HT Sequence Detection System (Applied Biosystems). A relative quantification method [1] was used to measure the amounts of ATP2B1 (TaqMan assay ID, Hs00155949_m1) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Hs99999905_m1) as an internal control. Genotype of ATP2B1 rs11105378 of each sample was analyzed by direct sequencing (BigDye Terminator v3.1 Cycle Sequencing Kit on a 3730xl GeneticAnalyzer, Applied Biosystems) using isolated genomic DNA from UASMCs (QIAamp DNA Mini Kit, QIAGEN GmbH, Hilden, Germany). The direct sequencing was performed with the following primers; forward 5'-TTCATAGCCCTTTTCATCTCTTTC-3', reverse 5'-AGAATCTCGGGAAAACAGCA-3'. Values are mean±SD. Cardiovascular disease (CVD); stroke, myocardial infarction, and angina pectoris. Hypertension; any or all of systolic blood pressure more than 140 mmHg, diastolic blood pressure more than 90 mmHg, and current use of antihypertensive agents. The Ohasama study conducted by Tohoku University is a population-based longitudinal epidemiological study focusing on the clinical implications of home BP measurement [2] . Ohasama Town is a rural community located in the northern part of Japan (Iwate Prefecture). Subjects were recruited through a community-based annual medical check-up process. The Shigaraki [3] and Takashima [4] | studies of Shiga University of Medical Science are general population-based longitudinal studies. Both towns are located in central Japan (Shiga Prefecture). Subjects were recruited through a community-based annual medical check-up process. The Suita study conducted by the National Cardiovascular Center is based on the residents of Suita city, an urban city located in the second largest area Osaka, Japan [5] . Subjects were recruited through a biennial medical check-up process of the National Cardiovascular Center. The Nomura study of Ehime University is a longitudinal epidemiological study based on the Nomura Town residents, a largely rural community located in Ehime Prefecture [6] . Subjects were recruited through a community-based annual medical check-up process. The Yokohama (Yokohama City University) and Matsuyama (Ehime University) cohorts are derived from employees of large manufacturing industries located in Kanagawa and Matuyama City, Ehime Prefecture (western part of Japan) [7] respectively. In all cohorts, clinical parameters were obtained from personal health records during the annual or biennial medical check-up process. All study procedures were approved by the ethics committee of each University or Institution. Singed informed consent was obtained from all participating subjects. Values are mean±SD. Nested hypertensive cases and normotensive control subjects were chosen from the cohort-based population sample according to the following criteria: hypertensive subjects aged 64 years or younger, and were either being treated with antihypertensive medication or had a SBP more than 160 mmHg and/or DBP more than 90 mmHg; normotensive subjects aged 40 years or older, and all of SBP less than 120 mmHg, and DBP less than 80 mmHg, no current use of antihypertensive medication, and free from any history of cardiovascular disease. Cardiovascular disease (CVD) includes stroke, myocardial infarction, and angina pectoris. The replication panel consists of 1,929 hypertensive cases and 1,993 normotensives controls selected from a 11,569 cohort sample (Table S2) . Antihypertensive medication (n (%)) 499 (65.8) -
Values are mean±standard deviation. Hypertensive cases: non-obese hypertensive patients, who had a previous diagnosis of hypertension at between 30 and 59 years of age, were either being treated with antihypertensive medication or had a SBP more than 160 mmHg and/or DBP more than 100 mmHg, had a family history of hypertension in their parents and/or siblings. Normotensive controls: middle-aged to elderly subjects (aged more than 45 years), who had never been treated with antihypertensive medications, had a SBP less than 120 mmHg and DBP less than 80 mmHg, and had no family history of hypertension. The screening panel is comprised of 758 middle age-onset severe hypertensive patients and 726 middle-aged to elderly evidently normotensive controls (Table   S4 ). NF; no genotype frequency The screening panel is comprised of 758 middle age-onset severe hypertensive patients and 726 middle-aged to elderly evidently normotensive controls (Table   S4) . 
28,866
In both Japanese Millennium GPJ and Global BP gen, hypertensive subjects were defined as being treated with antihypertensive medication, or SBP greater or equal to 140 mmHg, or DBP greater or equal to 90 mmHg; normotensive subjects were defined as all of not treated with antihypertensive medication, and SBP less or equal to 120 mmHg, and DBP less or equal to 85 mmHg [8] . Adjusted odds ratio was calculated under additive model using multiple logistic regression analysis adjusted for age, age 2 , sex, BMI, and cohort variables. Within Global BPgen, individual cohort results were combined using inverse variance weighted meta-analysis of the effects on a log-odds-ratio scale. The screening panel is comprised of 758 middle age-onset severe hypertensive patients and 726 middle-aged to elderly evidently normotensive controls (Table  S4 ). The replication panel consists of 1,929 hypertensive cases and 1,993 normotensives controls selected from a 11,569 cohort sample were enrolled (Table  S2) . Odds ratios and p-values for allelic model are shown. Coefficients and standardized error for systolic and diastolic BP were calculated under additive model using multiple regression analysis adjusted for age, age2, sex, BMI. Adjustment for treatment with antihypertensive medication was achieved by adding fixed constants to measured values (+15mmHg for SBP and +10mmHg for DBP). Coefficients for systolic and diastolic BP were calculated using multiple linear regression analysis adjusted cohort variables. Adjustment for treatment with antihypertensive medication was achieved by adding fixed constants to measured values (+15mmHg for SBP and +10mmHg for DBP). Hypertensive subjects were defined as being treated with antihypertensive medication, or SBP greater or equal to 140 mmHg, or DBP greater or equal to 90 mmHg; normotensive subjects were defined as all of not treated with antihypertensive medication, and SBP less or equal to 120 mmHg, and DBP less or equal to 85 mmHg [8] .
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